Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Ultragenyx Pharmaceutical Inc. 2/07 33,470 USD
+3,37% 		+3,37%
vlag uniQure N.V. 2/07 41,810 USD
-7,44% 		-7,44%
vlag UroGen Pharma Ltd 2/07 38,020 USD
+0,21% 		+0,21%

Nieuws over “Biotechnologie”

4/07 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

4/07 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

2/07 · Monthly information on share capital and company voting rights · Persbericht

2/07 · Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026 · Persbericht

2/07 · GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH · Persbericht

2/07 · Declaration voting rights - June 30,2026 · Persbericht

2/07 · ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 · Persbericht

1/07 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

1/07 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1/07 · ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1/07 · ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline · Persbericht

1/07 · Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test · Persbericht

1/07 · Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer · Persbericht

1/07 · ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit · Persbericht

30/06 · Halozyme Appoints David Ramsay as President Drug Delivery · Persbericht

30/06 · Acquisition of Own Shares · Persbericht

30/06 · Inkoop van eigen aandelen · Persbericht

30/06 · A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs · Persbericht

30/06 · COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT · Persbericht

30/06 · $ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action · Persbericht

30/06 · Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics · Persbericht

Mijn selecties